Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial by Conaghan, Philip G et al.
Extended report
Ann Rheum Dis 2011;70:1968–1974. doi:10.1136/ard.2010.146068 1968
Accepted 21 June 2011
Published Online First 
21 July 2011 
   ABSTRACT   
  Objective      T  o evaluate golimumab’s effect on MRI-
detected inﬂ  ammation and structural damage in 
patients with active rheumatoid arthritis (RA) despite 
methotrexate (MTX).   
  Methods      Patients (n=444) were randomly assigned 
to placebo plus MTX, golimumab 100 mg plus placebo, 
golimumab 50 mg plus MTX, or golimumab 100 mg plus 
MTX (subcutaneous injections every 4 weeks). A subset 
of 240 patients participated in an MRI substudy. MRIs 
(1.5T+contrast enhancement) of the dominant wrist 
and metacarpophalangeal (MCP) joints were obtained 
at baseline and weeks 12 and 24. Images were scored 
by two independent, blinded readers for synovitis 
(0–9 wrist only (n=240), 0–21 wrist+MCP (n=223)), 
bone oedema (osteitis) (0–69) and bone erosions 
(0–230) using the OMERACT Rheumatoid Arthritis MRI 
Scoring system.   
  Results      Signiﬁ  cant improvements in synovitis and 
bone oedema (osteitis) were observed in the combined 
golimumab plus MTX groups versus placebo plus MTX at 
week 12 (−1.77 vs −0.15, p<0.001 wrist+MCP and 
−2.00 vs 0.19, p=0.003, respectively) and week 24 
(−1.91 vs −0.38, p<0.001 wrist+MCP and −1.74 vs 
0.71, p=0.004, respectively). Fewer than 10% of patients 
had a substantial degree of erosive progression (most 
showed no progression) across all treatment groups 
(including the control group), precluding adequate 
evaluation of golimumab’s effect on bone erosions.   
  Conclusion      Golimumab plus MTX signiﬁ  cantly improved 
MRI-detected synovitis and osteitis (prognosticators 
of future structural damage) versus placebo plus MTX 
at weeks 12 and 24. The effect of golimumab on bone 
erosions could not be determined by semi-quantitative 
scoring in these RA patients with minimal progression of 
bone  erosions.      
  INTRODUCTION 
  Reducing inﬂ  ammation and consequently inhibit-
ing structural damage, thereby preserving patient 
function and quality of life, are the primary goals 
of rheumatoid arthritis (RA) therapy. Golimumab, 
a human, monoclonal antibody to tumour necrosis 
factor α (TNFα) agent, has demonstrated efﬁ  cacy in 
the treatment of established RA, including sustained 
improvement of clinical signs and symptoms, phys-
ical function and health-related quality of life in the 
GO-FORWARD study of patients with RA and inad-
equate response to methotrexate (MTX) therapy.  1     2   
In the analysis of GO-FORWARD radiographic data, 
minimal radiographic progression was observed 
in all treatment groups throughout the 24-week 
  placebo-controlled period, possibly due to low lev-
els of baseline disease activity. As a result, differ-
ences between the golimumab and placebo groups 
in the change in modiﬁ  ed Sharp scores from base-
line to week 24 were not statistically signiﬁ  cant.  3   
  While conventional radiographs remain the stan-
dard reference methods for assessing destructive 
skeletal changes in patients with RA, radiographs 
are inherently limited by the lack of ability to 
assess pre-erosive changes that precede damage to 
the osseous component of the joint, a stage of dis-
ease that had been thought to be irreversible.  4   In 
addition to being much more sensitive in detecting 
joint erosions,  5    –    10   MRI can also detect pre-erosive 
lesions (synovitis and osteitis). The areas of bone 
that appear as bone oedema or osteitis on MRI have 
been shown to be heavily inﬁ   ltrated by inﬂ  am-
matory cells including osteoclasts,  11   and MRI-
detected synovitis and osteitis have been shown to 
increase the risk of developing new   erosions over 
time as detected by either MRI or radiograph.  12    –    19   
Detection and treatment of pre-erosive lesions 
(synovitis and osteitis) can therefore signiﬁ  cantly 
alter the course of RA. 
  Very few large, randomised RA trials have 
included MRI assessments of pre-erosive lesions. 
The GO-FORWARD study of golimumab in the 
treatment of patients with established RA there-
fore included an MRI substudy to evaluate the 
effects of this anti-TNFα agent on MRI-assessed 
RA pathology.   
  PATIENTS  AND  METHODS 
  The study design and patient inclusion criteria of 
the GO-FORWARD study have been published 
elsewhere.  1   The overall GO-FORWARD study 
population consisted of patients (n=444) who had 
active RA despite MTX treatment. Patients were 
to have tolerated 15 mg/week or greater of MTX 
for at least 3 months before screening, with receipt 
of a stable MTX dose of 15 mg/week or greater 
but 25 mg/week or less during the 4-week period 
immediately preceding screening. A subset of the 
GO-FORWARD patients from eligible and willing 
sites participated in an MRI substudy (n=240). 
  The GO-FORWARD study was conducted 
according to the principles of the Declaration of 
Helsinki. As such, all patients provided written 
informed consent before participating in the study. 
▶    An additional supplementary 
table is published online only. 
To view this ﬁ   le please visit 
the journal online (  http://ard.
bmj.com ). 
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  Patients were randomly assigned to receive placebo injections 
plus MTX capsules (group 1), golimumab 100 mg injections plus 
placebo capsules (group 2), golimumab 50 mg injections plus 
MTX capsules (group 3) or golimumab 100 mg injections plus 
MTX capsules (group 4). Golimumab and placebo injections 
were administered subcutaneously every 4 weeks. At week 16, 
patients with <20% improvement in both tender and swollen 
joint counts entered double-blind early escape, in which patients 
in group 1 received golimumab 50 mg plus MTX, patients in 
group 2 received golimumab 100 mg plus MTX, and patients 
in group 3 received golimumab 100 mg plus MTX. Patients in 
group 4 who met the criteria for early escape did not have their 
study medication adjusted. Patients in group 1 who did not 
enter early escape crossed over to golimumab 50 mg plus MTX 
at week 24. Thus, the duration of the placebo-comparator por-
tion of the study was 24 weeks. 
  All patients a  t eligible (based on technical capabilities) and 
willing study sites participated in the MRI substudy. MRIs of the 
patient’s dominant wrist and metacarpophalangeal (MCP) joints 
were obtained at baseline and weeks 12, 24, 52, and 104 using 
1.5T MRI with contrast enhancement. The MR sequences were 
as follows: axial T1 fast spin echo (FSE) precontrast, coronal T1 
FSE precontrast, coronal short tau inversion recovery (STIR) (or 
T2 fat-suppressed precontrast) and coronal T1 fat-suppressed 
postcontrast. Additional details pertaining to the MRI procedure 
are provided in an online supplementary table. Results through 
week 24 are presented here. Images were scored by two inde-
pendent readers blinded to image time point or sequence, 
patient identity and treatment group. Readers scored synovi-
tis (0–9 for wrist joint, 0–21 for wrist plus MCP joints), bone 
oedema (osteitis) (0–69) and bone erosions (0–230), using the 
Rheumatoid Arthritis MRI Scoring (RAMRIS) system.  20   
  Randomised patients at MRI substudy sites with at least one 
MRI image scored by at least one reader were included in the 
MRI analyses (intent-to-treat population). For each patient at 
each visit, an MRI score was calculated as the average of each 
MRI score provided by the two primary independent readers. I  f 
a RAMRIS score from one of the readers was missing, then the 
RAMRIS score from the other reader was used. If the score was 
missing for both readers at any given time point, the average 
score was considered missing. 
  For patients who met the early escape criteria at week 16 in 
groups 1, 2 or 3, the week 12 MRI RAMRIS scores were car-
ried forward to week 24. The following missing data rules were 
applied for each RAMRIS score. (1) If the score was missing 
from baseline through week 12, the change score at week 12 
was imputed using the median change from baseline score of all 
patients at week 12. (2) If the week 12 score was missing, the 
week 12 score was imputed using the last non-missing obser-
vation (including baseline score). (3) If the baseline RAMRIS 
score was missing, the change score at week 12 was imputed 
using the median change from baseline score of all patients at 
week 12. Sensitivity analyses conducted included evaluation of 
change from baseline to week 24 with no imputation rules (ie, 
including only the 151 of the 240 (63%) MRI substudy patients 
who received subcutaneous study agent through week 24 with 
no missed doses and no missing baseline or week 24 data for all 
three RAMRIS scores) and evaluation of the RAMRIS bone ero-
sion score with linear extrapolation, which was undertaken for 
less than 37% of patients. 
  Changes from baseline to week 12 and week 24 in RAMRIS 
synovitis (wrist joints only in 240 patients and wrist plus MCP 
joints in 223 patients), bone oedema (osteitis) and bone erosion 
scores were compared between the treatment groups using a 
two-sided analysis of variance on the van der Waerden normal 
scores  21   at a 0.05 level of signiﬁ  cance. The primary comparison 
was between the combined golimumab plus MTX groups (goli-
mumab 50 mg plus MTX and golimumab 100 mg plus MTX) 
and the placebo plus MTX group. If the results of this compari-
son were statistically signiﬁ  cant, t  hen the individual golimumab 
dose groups were also compared with the placebo plus MTX 
group. The study, however, was not powered for these individ-
ual golimumab dose group comparisons with the placebo plus 
MTX group, and the sample size in each individual golimumab 
group in the MRI substudy may not have been large enough 
for reliable statistical analyses. This work, therefore, focused on 
comparisons for the combined golimumab plus MTX versus pla-
cebo plus MTX groups. 
  To assess reader reliability, images of 10% of patients were 
randomly selected and re-read by each of the two readers. Inter-
reader reliability and read-reread (intrareader) reliability coef-
ﬁ  cients (IRRC and RRRC, respectively) were estimated using 
the week 24 RAMRIS synovitis (wrist joints), bone erosion and 
bone oedema scores.  22     
  RESULTS 
  Of the 444 patients randomised to treatment in the 
GO-FORWARD study, 240 participated in the GO-FORWARD 
MRI substudy, including 72 patients in the placebo plus MTX, 
72 in the golimumab 100 mg plus placebo, 47 in the golimumab 
50 mg plus MTX, and 49 in the golimumab 100 mg plus MTX 
groups. The proportions of MRI substudy patients who met 
the early escape criteria (8–28%;   ﬁ  gure 1  ) were consistent with 
those for the overall GO-FORWARD population (11–31%) (data 
not shown).  1   Twenty of the 240 patients missed one or more 
MRI assessment visits, and all but one of the 240 patients had 
their MRI images scored by both readers.   
  Baseline demographics and disease characteristics of the MRI 
substudy patients were generally well balanced across the ran-
domised treatment groups, with the exception of lower mean 
baseline RAMRIS synovitis (wrist plus MCP), bone erosion and 
bone oedema (osteitis) scores in the golimumab 100 mg plus 
MTX group and a lower mean baseline C reactive protein (CRP) 
concentration in the placebo plus MTX group (  table 1  ). Baseline 
characteristics were also consistent with the baseline character-
istics of the overall GO-FORWARD patient population.  1   Mean 
baseline RAMRIS bone erosion scores ranged from 22.1 to 25.5, 
and mean duration of disease ranged from 8.0 to 9.5 years. Low 
levels of active inﬂ  ammation, as evidenced by median CRP con-
centrations ranging from 0.6 (placebo plus MTX group) to 1.0 
mg/dl (golimumab 100 mg plus placebo group), were observed 
across all randomised treatment groups (  table 1  ).   
  The IRRCs (inter-reader reliability) and RRRCs (intrareader 
reliability) based on week 24 RAMRIS scores were 0.96 and 
0.99, respectively, for bone erosion scores; 0.89 and 0.94, respec-
tively, for bone oedema scores; and 0.77 and 0.84, respectively, 
for synovitis. 
  Changes in RAMRIS scores from baseline to weeks 12 and 
24 are summarised in   table 2  . At week 12, signiﬁ  cant improve-
ments in the RAMRIS wrist plus MCP synovitis (−1.77 vs 
−0.15, p<0.001) and RAMRIS bone oedema (−2.00 vs 0.19, 
p=0.003) scores, but not in the RAMRIS bone erosion scores, 
were observed in the combined golimumab plus MTX group 
relative to the placebo plus MTX group, respectively (  table 2  , 
  ﬁ  gure 2  ). The IRRC and RRRCs for changes from baseline to 
week 24 were 0.80 and 0.73, respectively, for erosion, 0.81 and 
0.73, respectively, for oedema, and 0.80 and 0.74, respectively, 
for synovitis.       
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Similar response patterns were observed at week 24, with 
maintenance of the signiﬁ  cant improvements in the RAMRIS 
wrist plus MCP synovitis (−1.91 vs −0.38, p<0.001) and bone 
oedema (−1.74 vs 0.71, p=0.004) scores in the combined goli-
mumab plus MTX grou p relative to the placebo plus MTX group. 
Differences in the change from baseline to week 24 in RAMRIS 
bone erosion scores between the combined golimumab plus 
MTX and placebo plus MTX groups were not statistically signif-
icant. The percent changes from baseline to week 24 in RAMRIS 
synovitis (wrist plus MCP), bone oedema and bone erosion 
scores were −27.0%, −15.8% and +3.3%, respectively, in the 
combined golimumab plus MTX groups and +5.3%, +57.6% 
and +1.0%, respectively, in the   placebo plus MTX group. 
  Results of week 24 sensitivity analyses, including an analysis 
based on 153/240 (64%) patients with no missing data as well 
as evaluation of the RAMRIS bone erosion score with linear 
extrapolation (implemented for <36% of all substudy patients), 
were largely supportive of the results obtained in the primary 
analyses of RAMRIS scores (  table 2  ,   ﬁ  gure 2  ). 
  MRIs from a representative patient who was randomised 
to receive golimumab 100 mg plus placebo at baseline, week 
12 and week 24 are shown in   ﬁ  gure 3  . Coronal STIR images 
 Figure  1        Patient disposition in the GO-FORWARD MRI substudy. MTX, methotrexate.       
 Table  1        Baseline clinical characteristics for patients in the GO-FORWARD MRI substudy   
 Characteristic 
 Group  1   Group  2   Golimumab+MTX 
 Placebo+MTX 
 Golimumab  100 
mg+placebo    Group 3: 50 mg    Group 4: 100 mg    Groups 3 and 4 combined 
Randomised MRI substudy 
patients
72 72 47 49 96
Women, n (%) 61 (84.7%) 56 (77.8%) 41 (87.2%) 42 (85.7%) 83 (86.5%)
Age (years) 52.4 | 52.5 (45.0 to 59.0) 49.2 | 48.5 (41.5 to 57.5) 50.7 | 52.0 (42.0 to 58.0) 49.6 | 49.0 (44.0 to 53.0) 50.1 | 51.0 (43.0 to 57.0)
Disease duration (years) 9.3 | 6.5 (3.6 to 12.8) 8.5 | 6.5 (3.2 to 12.5) 8.0 | 5.3 (2.1 to 9.8) 9.5 | 6.8 (2.3 to 14.5) 8.8 | 6.1 (2.2 to 13.8)
Swollen joints (0–66) 13.8 | 10.0 (7.5 to 18.5) 13.6 | 10.0 (7.0 to 15.0) 15.7 | 10.0 (8.0 to 22.0) 12.7 | 11.0 (7.0 to 17.0) 14.2 | 11.0 (7.5 to 18.0)
Tender joints (0–68) 23.8 | 21.0 (13.5 to 32.0) 22.3 | 21.5 (11.0 to 28.5) 25.1 | 20.0 (11.0 to 38.0) 22.0 | 21.0 (11.0 to 29.0) 23.5 | 20.0 (11.0 to 32.5)
CRP (mg/dl) 1.2 | 0.6 (0.3 to 1.9) 2.1 | 1.0 (0.4 to 2.6) 1.9 | 0.8 (0.3 to 2.0) 1.5 | 0.9 (0.4 to 1.9) 1.7 | 0.9 (0.4 to 2.0)
ESR (mm/h) 35.3 | 35.5 (19.0 to 47.0) 41.9 | 39.0 (22.5 to 56.5) 41.2 | 38.0 (22.0 to 53.0) 39.7 | 34.0 (25.5 to 50.0) 40.5 | 36.0 (23.0 to 50.0)
vdH-S score (0–448) 40.4 | 21.5 (2.0 to 54.0) 39.1 | 17.3 (3.0 to 51.0) 31.0 | 7.3 (2.0 to 55.0) 31.1 | 13.5 (3.0 to 36.3) 31.0 | 13.0 (2.5 to 49.5)
RAMRIS scores
    Synovitis (wrist plus 
MCP) *   (0–21)
N=56, 6.7 | 6.8 
(3.3 to 9.3)
N=53, 7.3 | 7.5 
(2.5 to 10.5)
N=38, 7.6 | 7.8 
(4.1 to 10.5)
N=39, 6.3 | 6.6 
(3.0 to 8.5)
N=77, 7.0 | 7.0 
(4.0 to 9.5)
  Synovitis (wrist)  *   (0–9) N=67, 3.9 | 4.0 
(2.5 to 5.0)
N=62, 4.1 | 4.0 
(2.0 to 6.5)
N=43, 4.3 | 4.5 
(2.0 to 6.0)
N=44, 4.2 | 4.0 
(2.5 to 6.0)
N=87, 4.2 | 4.0 
(2.5 to 6.0)
  Bone oedema (0–69) N=67, 7.1 | 2.0 
(0.0 to 12.0)
N=62, 6.9 | 2.3 
(0.0 to 10.0)
N=43, 7.6 | 4.0 
(0.5 to 12.5)
N=45, 6.0 | 2.0 
(0.0 to 7.0)
N=88, 6.8 | 2.5 
(0.0 to 11.8)
  Bone erosion (0–230) N=68, 25.5 | 12.8 
(8.0 to 28.3)
N=62, 25.2 | 17.4 
(5.5 to 35.5)
N=43, 23.9 | 11.0 
(5.5 to 29.0)
N=45, 22.1 | 13.5 
(6.0 to 20.7)
N=88, 23.0 | 12.5 
(6.0 to 25.0)
      Data presented are n (%) or mean | median (IQR).   
    *    Due to an inability to obtain postgadolinium images of both the wrist and the metacarpophalangeal joints at the study site, 223 patients have RAMRIS synovitis scores of the wrist 
plus MCP joints and 240 patients have RAMRIS synovitis scores for the wrist joint only.   
    CRP, C reactive protein; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; MTX, methotrexate; RAMRIS, Rheumatoid Arthritis MRI Scoring system.     
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 Table  2        Summary o  f changes from baseline to weeks 12 and 24 in RAMRIS scores   
 Characteristic 
 Group  1   Group  2   Golimumab+MTX 
 Placebo+MTX 
 Golimumab  100 
mg+placebo    Group 3 50 mg    Group 4 100 mg    Groups 3 and 4 combined 
Randomised MRI substudy 
patients
72 72 47 49 96
RAMRIS synovitis (wrist plus MCP) score (n=223)  * 
 N=64 N=67 N=45 N=47 N=92
  Change from baseline to week 12
  Mean±SD −0.15±2.75 −0.78±2.58 −2.04±2.43 −1.54±2.63 −1.77±2.54
    Median (IQ range) −0.45 (−1.50 to 1.50) −0.31 (−2.00 to 0.50) −2.00 (−3.00 to −0.50) −2.00 (−3.20 to 0.50) −2.00 (−3.20 to 0.00)
  p  Value  †   0.30 <0.001 0.014 <0.001
  Change from baseline to week 24
  Mean±SD −0.38±2.66 −0.96±2.53 −1.85±2.28 −1.96±2.63 −1.91±2.45
    Median (IQ range) −0.50 (−1.45 to 1.00) −1.00 (−1.50 to 0.00) −1.75 (−3.00 to −0.50) −1.00 (−4.50 to 2.00) −1.00 (−3.13 to −0.33)
  p  Value   0.20 <0.001 0.003 <0.001
RAMRIS synovitis (wrist) score (n=240)  * 
  Change from baseline to week 12
  Mean±SD 0.08±1.51 −0.46±1.36 −1.13±1.61 −0.85±1.42 −0.98±1.51
    Median (IQ range) 0.00 (−1.00 to 1.00) 0.00 (−1.00 to 0.00) 1.00 (−2.00 to 0.00) −1.00 (−2.00 to 0.00) −1.00 (−2.00 to 0.00)
  p  Value   0.07 <0.001 0.002 <0.001
  Change from baseline to week 24
  Mean±SD 0.05±1.64 −0.56±1.46 −1.11±1.57 −1.16±1.70 −1.14±1.63
    Median (IQ range) 0.00 (−1.00 to 0.50) −0.50 (−1.00 to 0.00) −0.50 (−2.00 to 0.00) −0.50 (−4.50 to 2.00) −0.50 (−2.00 to 0.00)
  p  Value   0.029 <0.001 <0.001 <0.001
  Sensitivity analysis for week 24 data (available data only/no imputation for missing data  ‡ )
 N=49 N=44 N=28 N=30 N=58
  Mean±SD 0.16±1.78 −0.56±1.59 −1.19±1.49 −1.48±1.89 −1.34±1.70
    Median (IQ range) 0.00 (−0.75 to 1.00) −0.50 (−1.25 to 0.50) −1.00 (−2.00 to 0.00) −1.50 (−3.00 to 0.00) −1.00 (−3.00 to 0.00)
  p  Value   0.037 <0.001 <0.001 <0.001
RAMRIS bone oedema (osteitis) score
  Change from baseline to week 12
  Mean±SD 0.19±7.52 −2.11±4.99 −2.81±5.12 −1.31±3.49 −2.00±4.36
    Median (IQ range) 0.00 (−1.00 to 1.50) 0.00 (−2.07 to 0.00) −0.50 (−4.50 to 0.00) −0.03 (−1.50 to 0.00) −0.50 (−2.09 to 0.00)
  p  Value   0.007 0.002 0.07 0.003
  Change from baseline to week 24
  Mean±SD 0.71±7.54 −1.28±3.94 −2.58±4.75 −0.92±3.38 −1.74±4.17
    Median (IQ range) 0.00 (−0.50 to 0.50) 0.00 (−1.50 to 0.00) −0.50 (−4.09 to 0.00) 0.00 (−1.60 to 0.00) 0.00 (−2.19 to 0.00)
  p  Value   0.11 <0.001 0.177 0.004
  Sensitivity analysis for week 24 data (available data only/no imputation for missing data  ‡ )
 N=49 N=44 N=29 N=30 N=59
  Mean±SD 0.68±5.35 −1.66±4.64 −3.20±5.52 −1.14±3.84 −2.15±4.81
    Median (IQ range) 0.00 (−0.50 to 0.55) 0.00 (−2.00 to 0.00) −1.00 (−3.64 to 0.00) 0.00 (−2.00 to 0.00) −0.50 (−3.07 to 0.00)
  p  Value   0.05 <0.001 0.10 0.002
RAMRIS bone erosion score
  Change from baseline to week 12
  Mean±SD −0.76±3.54 0.50±2.93 −1.28±4.80 −0.80±6.67 −1.02±5.85
    Median (IQ range) 0.00 (−0.50 to 0.07) 0.00 (0.00 to 0.50) 0.00 (−0.50 to 0.00) 0.00 (−0.10 to 0.41) 0.00 (−0.50 to 0.00)
  p  Value   0.038 0.36 0.32 0.90
  Change from baseline to week 24
  Mean±SD −0.47±3.40 0.40±2.62 −1.08±4.35 −0.78±6.48 −0.92±5.51
    Median (IQ range) 0.00 (−0.50 to 0.00) 0.00 (0.00 to 0.02) 0.00 (−0.50 to 0.00) 0.00 (−0.09 to 0.18) 0.00 (−0.19 to 0.00)
  p  Value   0.14 0.21 0.68 0.62
  Sensitivity analysis for week 24 data (available data only/ no imputation for missing data  ‡ )
 N=50 N=44 N=29 N=30 N=59
  Mean±SD −0.56±4.01 0.22±2.43 −1.46±5.38 −1.53±8.18 −1.50±6.89
    Median (IQ range) 0.00 (−0.50 to 0.39) 0.00 (0.00 to 0.45) 0.00 (−0.50 to 0.00) 0.00 (−0.50 to 0.32) 0.00 (−0.50 to 0.00)
  p  Value   0.42 0.16 0.62 0.26
 Linear  extrapolation  § 
  Mean±SD −0.90±5.23 0.55±3.96 −1.54±5.03 −0.65±6.63 −1.09±5.89
    Median (IQ range) 0.00 (−0.50 to 0.32) 0.00 (0.00 to 0.27) 0.00 (−0.83 to 0.00) 0.00 (−0.09 to 0.32) 0.00 (−0.40 to 0.00)
  p  Value   0.33 0.22 0.60 0.68
      All analyses are based on the 240 randomised substudy patients unless otherwise noted in the table.   
    *    Due to an inability to obtain postgadolinium images of both the wrist and the metacarpophalangeal joints at the study site, 223 patients have RAMRIS synovitis scores of the wrist 
plus MCP joints and 240 patients have RAMRIS synovitis scores for the wrist joint only.   
  †    All p values derive from statistical comparisons versus group 1.   
  ‡    The sensitivity analysis employing no imputation rules included the 153/240 (64%) substudy patients who received subcutaneous study agent through week 24 with no missed doses 
and no missing baseline or week 24 data.   
    §    Evaluation of the RAMRIS bone erosion score with linear extrapolation was implemented for less than 36% of all substudy patients.   
  MCP, metacarpophalangeal; MTX, methotrexate; RAMRIS, Rheumatoid Arthritis MRI Scoring system. 
15_annrheumdis146068.indd   1971 15_annrheumdis146068.indd   1971 9/23/2011   11:57:00 AM 9/23/2011   11:57:00 AMExtended report
Ann Rheum Dis 2011;70:1968–1974. doi:10.1136/ard.2010.146068 1972
(  ﬁ  gure  3A  –  C  ) show that extensive bone oedema in many 
wrist bones at baseline (  ﬁ  gure 3A  ) was markedly decreased at 
week 12 (  ﬁ  gure 3B  ) and nearly resolved at week 24 (  ﬁ  gure 3C  ). 
Corresponding postcontrast T1-weighted images with fat 
  suppression (    ﬁ  gure 3D  –  F  ) show substantial synovitis at base-
line (  ﬁ  gure 3D  ) that was markedly reduced at week 12 (  ﬁ  gure 
3E  ) and almost resolved at week 24 (  ﬁ  gure  3F  ). Precontrast 
T1-weighted images without fat suppression (  ﬁ  gure 3G  –  I  ) show 
 Figure  2     Changes from baseline to weeks 12 and 24 in synovitis (wrist plus metacarpophalangeal (MCP) joints (A), bone oedema (osteitis) 
(B) and bone erosion (C)). Each graph shows the mean (solid horizontal line), median (dotted horizontal line) and IQR (grey bars) for changes from 
baseline for each treatment group. P values are for the comparison of each golimumab treatment group with placebo using analysis of variance on 
the van der Waerden normal scor  es, with *, ** and *** indicating p<0.05, <0.01 and <0.001, respectively. GLM, golimumab; MTX, methotrexate; 
PBO, placebo; RAMRIS, OMERACT Rheumatoid Arthritis MRI Score.       
 Figure  3     MRI of the wrist at baseline (A, D, G), week 12 (B, E, H) and week 24 (C, F, I) of a patient randomised to receive golimumab 100 mg plus 
placebo. Co  ronal short tau inversion recovery (STIR) images (A–C) show extensive bone oedema at baseline (A). The bone oedema has markedly 
decreased at week 12 (B) and has nearly resolved at week 24 (C). Corresponding postcontrast T1-weighted images with fat suppression (D–F) show 
substantial synovitis at baseline (D) and markedly reduced synovitis at week 12 (E) and week 24 (F). Precontrast T1-weighted images without fat 
suppression (G–I) show no progression of bone erosion during the 24-week follow-up period. Note: Series of consecutive images were evaluated; the 
images displayed here are representative but not exhaustive.       
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no progression of bone erosion during the 24-week follow-up 
period.     
  DISCUSSION 
  We evaluated a large MRI substudy of the GO-FORWARD trial, 
a randomised, controlled study in which the efﬁ  cacy and safety 
of golimumab were assessed in patients with active RA despite 
MTX therapy. Serial measurements of synovitis, bone oedema 
(osteitis) and bone erosion were obtained using the RAMRIS 
system, which has demonstrated very good reliability and a high 
level of sensitivity to change.  23   We also observed good inter-
reader and intrareader reliability for the pathological features 
scored. Results of this MRI substudy demonstrated that patients 
who received golimumab plus MTX had improvements in syno-
vitis and osteitis that exceeded those observed with receipt of 
placebo plus MTX as early as week 12 and continuing through 
week 24. Results of sensitivity analyses were largely supportive 
of the primary analyses. 
  The GO-FORWARD study results pertaining to signs and 
symptoms, safety and radiographic data have been reported 
previously.  1    –    3   These results demonstrated that the addition of 
golimumab to MTX in patients with active RA despite MTX 
therapy signiﬁ  cantly reduced the signs and symptoms of RA 
and improved physical function, wh  ile yielding a safety pro-
ﬁ  le consistent with those of other anti-TNF agents. The mini-
mal radiographic progression observed across all treatment 
groups through the 24-week placebo-controlled phase of 
GO-FORWARD, which was likely to have been related to the 
low levels of baseline active inﬂ  ammation (as assessed by CRP 
levels), precluded adequate assessment of golimumab’s effect on 
radiographic progression in these patients with established RA.  3   
It has been noted that the severity of overall disease and joint 
damage in the population of RA patients recruited into clinical 
studies may be decreasing over time,  24   and patients with low 
CRP levels are known to have less radiographic progression 
over time than those with high CRP levels.  25   As discussed in 
detail by Emery and colleagues,  3   it is likely that CRP, as a marker 
of active inﬂ  ammation in RA, is a more important predictor of 
radiographic progression than baseline radiographic score since 
radiographic damage is less likely to progress if there is no active 
inﬂ  ammation, regardless of the level of damage at baseline. For 
instance, RA patients with an inadequate response to MTX in 
the RAPID1 study of certolizumab  26   had median baseline CRP 
levels of ~1.6 mg/dl, compared with ~0.9 mg/dl in the current 
study. Despite having similar levels of radiographic damage at 
baseline, with modiﬁ  ed Sharp scores of ~35 in GO-FORWARD 
and ~39 in RAPID1, the average change in modiﬁ  ed  Sharp 
score (ie, progression) observed from baseline to week 24 was 
greater in the control group of RAPID1 (1.3) than in group 1 of 
GO-FORWARD (0.6).  3     26   Also of note, in a different golimumab 
MRI substudy, conducted in MTX-naive RA patients, median 
baseline CRP levels were higher (1.1–1.5 mg/dl) than in the cur-
rent study of MTX-experienced patients (0.6–1.0 mg/dl) and the 
difference between the placebo plus MTX and combined goli-
mumab plus MTX groups for RAMRIS erosion change scores 
was statistically signiﬁ  cant.  27   
  MRI has been shown to be more sensitive to changes in bone 
erosions than radiographs.  5    –    10   Thus, the expectation was that 
MRI would detect a difference among the GO-FORWARD treat-
ment groups in the progression of bone erosion despite the fact 
that radiographic evaluation could not.  3   The fact that only mini-
mal progression of bone erosion was observed even with MRI 
conﬁ  rms that these patients did indeed have minimal progression 
in structural damage during the 6-month study period. However, 
the fact that golimumab plus MTX has been shown to signiﬁ  -
cantly improve pre-erosive inﬂ  ammation, which is predictive of 
future bone erosion,  12    –    19   relative to placebo plus MTX is very 
important, especially in light of the low levels of baseline dis-
ease activity observed in this particular patient population. All 
patients in the GO-FORWARD study receive golimumab treat-
ment beyond 6 months, and it is expected that the beneﬁ  cial 
effects of golimumab plus MTX on synovitis and bone oedema 
(osteitis) may prevent further progression of structural damage. 
While some low level MRI-documented progression of erosions 
was observed in terms of mean change in patients treated with 
golimumab 100 mg monotherapy, it is possible that this change 
was within the measurement error given the range of scores for 
this scale. 
  As discussed, the RA patient population enrolled in this study 
actually had a low degree of active inﬂ  ammation and thus mini-
mal radiographic (erosion and joint space narrowing) progres-
sion. This may have limited evaluation of golimumab’s effect on 
RAMRIS erosion scores.  3   The limited radiographic progression 
observed in this study is not unique to golimumab. In an evalu-
ation of 51 RA patients receiving adalimumab plus MTX combi-
nation therapy, no overall erosive progression or repair occurred, 
whereas repair of individual erosions was documented on MRI, 
and MRI and ultrasonography synovitis decreased.  28   In a sepa-
rate study, progression to radiographic erosion occurred rarely in 
a cohort of 50 RA patients exposed to potent disease-suppress-
ing therapies that included TNF inhibitors, MTX and leﬂ  uno-
mide.  29   Another possible limitation to this study is that it does 
represent a subpopulation of the larger trial; however, the popu-
lations in each treatment arm reﬂ  ected the characteristics of the 
full trial groups. While the responsiveness of the RAMRIS score, 
especially in terms of assessing erosive disease, requires further 
evaluation, at present this semi-quantitative score remains the 
standard for assessing RA MRI trials. 
  Overall, results of the GO-FORWARD MRI substudy have 
demonstrated a signiﬁ  cant reduction in pre-erosive lesions (syn-
ovitis and osteitis) using golimumab plus MTX compared with 
MTX alone, even in this study population with low levels of dis-
ease activity. MRI allows measurement of inﬂ  ammatory lesions 
such as osteitis and synovitis, as well as erosions, and thus is 
an important tool for objectively evaluating the effect of newer 
compounds on disease activity in future clinical trials enrolling 
patient populations with relatively lower disease activity. 
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